Medivation Announces Topline Results From Phase 2 STRIVE Trial - Quick Facts

(RTTNews) - Astellas Pharma Inc. and Medivation, Inc. (MDVN) announced topline results from the Phase 2 STRIVE trial comparing enzalutamide with bicalutamide in a study population of men with non-metastatic or metastatic castration-resistant prostate cancer.

The company said the study achieved its primary endpoint demonstrating a statistically significant increase in progression-free survival or PFS for enzalutamide compared with bicalutamide. Median PFS was 19.4 months in the enzalutamide group compared with 5.7 months in the bicalutamide group.

The STRIVE study is the second of two head-to-head studies of enzalutamide versus bicalutamide, the first of which was TERRAIN. Additional results from the STRIVE trial, including the secondary endpoints and safety data, will be submitted for presentation at upcoming medical conferences.